RA Capital Management’s Cytek Biosciences CTKB Stock Holding History

RA Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,809,404	Closed	-$45.7M	–	81
2024 Q1	$45.7M	Hold	6,809,404	–	–	0.58%	44
2023 Q4	$62.1M	Hold	6,809,404	–	–	0.97%	26
2023 Q3	$37.6M	Sell	6,809,404 -5,488,317	-45%	-$44M	0.74%	37
2023 Q2	$105M	Sell	12,297,721 -1,083,333	-8%	-$9.72M	1.98%	12
2023 Q1	$123M	Hold	13,381,054	–	–	2.78%	8
2022 Q4	$137M	Hold	13,381,054	–	–	2.77%	10
2022 Q3	$197M	Hold	13,381,054	–	–	4.2%	3
2022 Q2	$144M	Hold	13,381,054	–	–	3.83%	3
2022 Q1	$144M	Buy	13,381,054 +3,774,026	+39%	+$51M	3.15%	4
2021 Q4	$157M	Hold	9,607,028	–	–	2.76%	6
2021 Q3	$206M	Buy	+9,607,028	New	+$226M	2.85%	6

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RA Capital Management's CTKB Position: Q2 2024 in Review

RA Capital Management sold out of Cytek Biosciences (CTKB) in Q2 2024, closing a stake of 6,809,404 shares — an estimated $45.7M sold.

RA Capital Management first reported a position in CTKB in Q3 2021 and held it in 11 quarters. The position peaked at $206M in Q3 2021. 128 funds tracked by Wall St. Rank hold CTKB as of Q2 2024.

RA Capital Management reported no remaining Cytek Biosciences position as of Q2 2024 after selling out during the quarter.
RA Capital Management sold 6,809,404 Cytek Biosciences shares in Q2 2024, an estimated $45.7M.
RA Capital Management first reported a position in Cytek Biosciences in Q3 2021 and held it in 11 quarters.
RA Capital Management's Cytek Biosciences position peaked at $206M in Q3 2021.
128 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2024.

Based on RA Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.